2026-09-14T05:46:06Zhttps://gredos.usal.es/oai/request

oai:gredos.usal.es:10366/1690622026-01-21T01:02:27Zcom_10366_3974com_10366_3947com_10366_3946com_10366_3823col_10366_3975

Autologous mesenchymal stem cell transplantation for spinal fusion: 10 years follow-up of a phase I/II clinical trial Gómez Ruiz, Victoria Blanco Blanco, Juan Francisco Villarón Ríos, Eva María Fidalgo, Helena López Parra, Miriam Sánchez Guijo Martín, Fermín Mesenchymal stem cells Spinal fusion Bone graft Intervertebral disc degeneration Cell transplantation Intervertebral Disc Degeneration Mesenchymal Stem Cell Transplantation Cell Transplantation trasplante de células degeneración del disco intervertebral trasplante de células madre mesenquimatosas [EN]Posterolateral spinal fusion is the standard surgical approach for patients with degenerative disc disease. In our previously published article, we reported a 5-years follow-up of a phase I/II clinical trial in patients undergoing spinal fusion with autologous mesenchymal stem cells (MSCs) embedded in tricalcium phosphate. In the current manuscript, we have updated the results with a 10-year follow-up, the longest reported to date in this setting. After clinical and radiological evaluation, safety of the procedure was further confirmed in all 11 treated patients, with no evidence of tumor, infection, inflammatory reaction, or heterotopic ossification related to the administration of MSCs. Regarding clinical efficacy, low back pain and radicular pain (both assessed by the visual analogue scale—VAS), and the Owestry Disability Index remained significantly lower compared to pre-intervention. Radiologic evaluation demonstrated spinal fusion in all cases, improving over time. Finally, quality of life improved significantly also during follow-up. In summary, the use of tricalcium phosphate-embedded autologous MSCs with lumbar posterolateral arthrodesis is safe and potentially provides long-term benefits for 10 years. 2026-01-20T12:04:21Z 2026-01-20T12:04:21Z 2023 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Gomez-Ruiz, V., Blanco, J. F., Villarón, E. M., Fidalgo, H., López-Parra, M., & Sánchez-Guijo, F. (2023). Autologous mesenchymal stem cell transplantation for spinal fusion: 10 years follow-up of a phase I/II clinical trial. Stem cell research & therapy, 14(1), 78. https://doi.org/10.1186/S13287-023-03298-4 http://hdl.handle.net/10366/169062 10.1186/S13287-023-03298-4 1757-6512 eng https://doi.org/10.1186/s13287-023-03298-4 Attribution-NonCommercial-NoDerivatives 4.0 Internacional http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess Bentham Science Publishers https://gredos.usal.es/bitstream/10366/169062/5/Autologous%20mesenchymal%20stem%20cell%20transplantation%20for%20spinal%20fusion.pdf.jpg Hispana TEXT http://creativecommons.org/licenses/by-nc-nd/4.0/ Gredos. Repositorio Documental de la Universidad de Salamanca http://hdl.handle.net/10366/169062